990 N.E.2d 997 (Mass. 2013)
Tobacco. Wrongful Death. Negligence, Wrongful death, Duty to warn, Defective product, Adequacy of warning, Comparative, Gross negligence. Consortium. Parent and Child, Consortium. Wilful, Wanton, or Reckless Conduct. Conscious Pain and Suffering. Consumer Protection Act, Unfair or deceptive act. Uniform Commercial Code, Warranty. Warranty. Damages, Wrongful death, Loss of consortium, Punitive, Conscious pain and suffering. Jury and Jurors. Practice, Civil, Wrongful death, Challenge of jurors, Bias of judge, Mistrial, Dismissal, Instructions to jury. Collateral Estoppel. Estoppel. Res Judicata. Limitations, Statute of. Evidence, Findings in another proceeding, Relevancy and materiality.
In a wrongful death action brought by the estate of a deceased cigarette smoker against the designer and manufacturer of the brand of cigarettes she smoked (defendant), based on theories of liability including, inter alia, breach of the implied warranty of merchantability, the judge did not err in instructing the jury that they "may," rather than "must," consider whether the defendant's brand of cigarettes met consumers' reasonable expectations as to safety; further, the evidence was sufficient as a matter of law to support a finding that a rational, informed consumer, whose freedom of choice is not substantially impaired by addiction, would perceive a low tar, low nicotine cigarette as constituting a safer, reasonable alternative to the defendant's brand of cigarettes; finally, viewing the evidence in the light most favorable to the estate, a reasonable jury could find that the defendant failed to provide the decedent an adequate warning of the health hazard or addictive properties of its brand of cigarettes, in that the risks of cigarette smoking certainly were not obvious during the relevant time period, and in that the decedent was not aware of the health risks of smoking at the time she began to smoke as a teenager and did not appreciate the danger of smoking the defendant's brand of cigarettes.
In a wrongful death action brought by the estate of a deceased cigarette smoker against the designer and manufacturer of the brand of cigarettes she smoked (defendant), based on theories of liability including, inter alia, negligence in the design, marketing, and distribution of the defendant's brand of cigarettes, the judge erred in instructing the jury that they "may" but not were not required to consider whether there was a safer alternative design available; further, the judge erred in failing to provide the jury guidance as to the meaning of negligent marketing and the limits of a manufacturer's duty regarding marketing.
This court concluded that the designer and manufacturer of a certain brand of cigarettes did not voluntarily assume a duty to research the health hazards of smoking and to disclose accurate information regarding the results of that research to the general public when that designer-manufacturer, along with other manufacturers of cigarettes, issued a certain newspaper advertisement.
This court vacated the award of punitive damages in a wrongful death action brought against the designer and manufacturer of a certain brand of cigarettes (defendant), where this court could not be confident that the jury's findings that the defendant was grossly negligent and had acted in a manner that was malicious, wilful, wanton, or reckless were untainted by error.
The claims in a wrongful death action brought by the estate of a deceased cigarette smoker against the designer and manufacturer of the brand of cigarettes she smoked were not time barred, where the decedent's cause of action for injuries resulting from her lung cancer accrued when she knew or reasonably should have known that she had developed lung cancer from smoking the defendant's brand of cigarettes, which occurred when she was diagnosed with metastatic small cell lung cancer; and where the estate's claims were brought within the three-year statute of limitations period.
At the trial of a civil complaint, the judge did not abuse her discretion in conducting voir dire of the venire when she denied the defendant's request for a jury questionnaire; further, although the judge, having represented that fourteen jurors would be chosen, should not have seated a fifteenth juror without giving the parties an additional peremptory challenge, the defendant failed to show that, had it been given an additional challenge, it would have struck the fifteenth juror.
At the trial of a civil complaint, the defendant was not denied its due process right to an impartial judge, where certain statements that the judge made did not reasonably suggest that she was partial.
At the trial of a civil complaint, although the judge erred in directing the plaintiff to misrepresent findings from another trial as the findings of an expert to impeach a defense witness, the error was not consequential, in that the witness's opinion was unaffected by the line of questioning, the jury were unlikely to be swayed by the hypothetical opinions of an unidentified expert, and this court vacated on other grounds the jury's findings of liability on the claims to which this line of questioning related.
In a wrongful death action brought by the estate of a deceased cigarette smoker (an African-American) against the designer and manufacturer of the brand of cigarettes she smoked (defendant), the judge did not err in admitting evidence that the defendant marketed cigarettes to the African-American community before 1970, where the evidence tended to show whether the risks of smoking were obvious and, if not, whether such risks were adequately warned of during that time period; further, any material risk of prejudice arising from the erroneous admission of evidence of marketing to the African-American community after 1970 (which was irrelevant to any claim in the case) or from evidence that the defendant marketed and distributed cigarettes to minors after the decedent had become an adult was eliminated by this court's vacating of the jury's finding on negligence liability.
In a wrongful death action brought by the estate of a deceased cigarette smoker against the designer and manufacturer of the brand of cigarettes she smoked (defendant), the judge did not err in admitting in evidence certain testimony from the defendant's then chairman and chief executive officer, given to a congressional subcommittee in 1994, where the testimony was relevant to rebut the defendant's assertion that the risks of smoking were so well known before 1970 that the defendant had no duty to warn.
In a wrongful death action brought by the estate of a deceased cigarette smoker against the designer and manufacturer of the brand of cigarettes she smoked (defendant), the judge did not abuse her discretion in precluding testimony regarding the color of packages of cigarettes not manufactured by the defendant, where the witness offering the testimony lacked personal knowledge of the color of cigarette packages during the relevant time period, and where the observable color of a cigarette package is not a proper subject matter for expert opinion; further, the judge did not abuse her discretion in precluding testimony about the proportional market shares of certain brands of cigarettes.
At the trial of a civil complaint, the judge did not abuse her discretion in denying a motion for a mistrial based on a question posed by plaintiff's counsel to a defense witness, in which counsel allegedly impugned the integrity of the defendant's attorneys, where, while the question at issue was improper as phrased, the inquiry itself was not improper; where the judge sustained the objection in front of the jury and invited defense counsel to suggest a limiting instruction; and where the judge in final instructions stated that a question not answered (such as the one at issue) was not to be considered at all.
At a civil trial, no reasonable risk arose that the jury's verdict was affected by the admission in evidence of two exhibits to which the defendant objected based on authenticity.
At a civil trial, the judge acted within her discretion in allowing, over objection, the plaintiff's motion to dismiss one of its claims after the jury had indicated they were at an impasse on that claim; further, the defendant could not have been prejudiced as to the remaining claims by the jury learning during deliberations that the one claim had been withdrawn from their consideration, and allowing the dismissal did not result in the jury improperly considering evidence no longer relevant to any claim before them.
This court concluded that the award of compensatory damages in a civil action, after remittitur, was not disproportionate to the injuries suffered and did not represent a miscarriage of justice.
This court vacated a judgment of unfair or deceptive acts or practices in trade or commerce in violation of G. L. c. 93A, § 2, in a wrongful death action brought by the estate of a deceased cigarette smoker against the designer and manufacturer of the brand of cigarettes she smoked (defendant), where the unfortunate phrasing of the judge's finding of negligence in the "design, marketing, and/or distribution" of cigarettes prevented this court from being certain that the judge found the defendant negligent in the design of its cigarettes and the evidence did not support a conclusion that the defendant's negligent marketing or distribution of cigarettes to minors caused injury to the decedent at a time when she was an adult; where the judge erred in concluding that the defendant had violated G. L. c. 93A in committing a breach of a voluntarily assumed duty; and where the judge erred in applying principles of offensive collateral estoppel in adopting certain findings of a judge in another case, in that the issues decided in that case were not identical to the issues in the case at bar.
Marie R. Evans (Marie) died in 2002, at the age of fifty-four, from small cell lung cancer caused by smoking cigarettes. A jury found that the defendant, Lorillard Tobacco Company (Lorillard), the designer and manufacturer of Newport brand cigarettes, caused her wrongful death based on various theories of liability: breach of the implied warranty of merchantability because of design defect and inadequate warning of Newport cigarettes' health hazards and addictive properties; negligence in the design, marketing, or distribution of Newport cigarettes; negligent distribution by giving free samples of Newport cigarettes to minors; and negligent performance of a duty Lorillard voluntarily undertook in 1954 to research the health hazards of smoking and disclose accurate information regarding the results of that research to the smoking public. As to the negligence claims, the jury found Marie also to be negligent, and apportioned thirty per cent of the comparative negligence to her. The jury awarded $21 million to her son, Willie Evans (plaintiff), for the loss of his mother's companionship, comfort, and counsel; and $50 million to Marie's estate for her conscious pain and suffering. The jury also found that Lorillard was grossly negligent and acted in a manner that was malicious, wilful, wanton, or reckless, and awarded punitive damages in the amount of $81 million. The judge found that Lorillard had violated G. L. c. 93A, § 2, but did not award any additional compensatory or punitive damages for its violation, finding that any further award of damages would be "duplicative" of the jury's award.
Following trial, Lorillard moved for judgment notwithstanding the verdict, a new trial, remittitur, and amendment of the G. L. c. 93A decision. The judge denied the posttrial motions except for the motion for remittitur, which she allowed in part, reducing the amount of compensatory damages to the plaintiff to $10 million, and to Marie's estate to $25 million, but denying any remittitur as to punitive damages. The plaintiff accepted the remittitur, Lorillard appealed from the judgment, and we granted the plaintiff's application for direct appellate review.
We affirm the judgment only in part. We conclude that the jury were adequately instructed regarding the claim of wrongful death based on the breach of the implied warranty of merchantability, that the evidence supports the jury's verdict finding such a breach, that this breach alone supports the jury's finding of wrongful death, and that the errors at trial did not deny Lorillard a fair trial as to this claim. But we conclude that the jury were not adequately instructed regarding the claim of wrongful death based on the theories of negligent design and marketing, and that the jury's findings on these theories must be vacated. Because the verdict form asked the jury to determine whether Marie's wrongful death was caused by Lorillard's negligence, and did not request separate findings of causation based on each theory of negligence, we must also vacate the jury's finding that Marie's wrongful death was caused by Lorillard's negligence because the jury may have found that Marie's death was caused by negligent design or marketing, rather than negligent failure to warn or the negligent distribution of cigarettes to minors. We also conclude that, even if Lorillard did not honor its public commitment in 1954 to "accept an interest in people's health as a basic responsibility, paramount to every other consideration in our business," Lorillard did not, by making this statement, voluntarily undertake a legal duty whose negligent breach provides a separate ground to find wrongful death. Because the jury's award of compensatory damages, as reduced by the remittitur, adequately rests on the finding of breach of the implied warranty of merchantability, we affirm that award. However, we vacate the award of punitive damages because it may have been tainted by the errors regarding the theories of negligent design and marketing and the breach of a voluntarily undertaken duty, and we remand the case for a new trial on the issue of punitive damages.
We also vacate the judgment arising from the judge's finding that Lorillard committed unfair or deceptive acts or practices in the conduct of trade or commerce, in violation of G. L. c. 93A, § 2 (§ 2). We conclude that the judge erred in finding that Lorillard voluntarily undertook a legal duty through its public commitment in 1954, and that the judge improperly applied the doctrine of offensive collateral estoppel against Lorillard by adopting over thirty-eight findings from a Federal racketeering case against Lorillard and other cigarette manufacturers. In addition, because the judge found that Lorillard "was negligent in the design, marketing, and/or distribution of Newport cigarettes" (emphasis added), the judge's finding of negligence was potentially based exclusively on a theory of either negligent marketing or distribution, and not on a theory of negligent design. However, any negligence in Lorillard's marketing or distribution of its cigarettes to minors could not have caused injury to Marie after 1979, because she was an adult by 1979. Because these various errors, when considered cumulatively, may have affected the judge's ultimate determination that Lorillard caused injury to Marie after 1979 through its violation of § 2, we conclude that the prudent course is to vacate the judgment on the plaintiff's claim under c. 93A and remand the case to the judge. On remand, the judge shall determine whether, based solely on the relevant evidence presented at trial, Lorillard violated § 2, and, if liability is found under G. L. c. 93A, § 9, what actual damages should appropriately be awarded to Marie's estate for injury suffered by her that was caused by the § 2 violation. If the judge finds a violation of § 2, the judge shall also determine whether the violation was wilful or knowing and, if so, whether actual damages should be doubled or trebled in accordance with G. L. c. 93A, § 9(3).
Background. Because Lorillard contends that the evidence is insufficient as a matter of law to sustain the jury's verdict, we summarize the evidence at trial in the light most favorable to the plaintiff. We reserve our recitation of some of the evidence for our analysis of Lorillard's specific claims of error.
When she was a child and teenager, she heard people refer to cigarette smoking as an addiction. She remembered the 1964 United States Surgeon General's report describing cigarette smoking as habit forming and as a cause of lung cancer. However, she testified that she was not convinced by these statements:
"[I]t was, you know, one of those two sides to every story. It was like, one day it would come out saying it was bad for you. The next day it was good for you. And it was kind of always a debate going on whether or not it caused cancer or didn't, or if it was something else. And so it became something that you really didn't rely on anyone's opinion as to being the true cause of what causes cancer."
As an adult, Marie smoked an average of thirty Newport cigarettes each day — one and one-half packs of cigarettes. She was so addicted to cigarettes that she would smoke within five minutes of waking up each morning. At least ninety per cent of the cigarettes she smoked in her life were Newports. She once tried Merit, another brand of cigarette, because it was supposed to be less harmful, but she did not like the taste.
In 1970, when Marie's father died from lung cancer, she drew a connection between her father's lung cancer and his having been a "lifelong smoker," but she "gave no thought" as to the cause of his lung cancer. She became convinced that smoking was bad for her health in 1985 when she had a heart attack. During the remainder of her life, she tried to quit smoking more than fifty times, but she never succeeded. In her own words:
"I tried everything. Nothing worked. I tried to quit smoking certainly immediately. I was unable to. By then, it was too late; I was addicted to it. I went to several places, spent thousands of dollars trying to find a cure, tried to help myself, psychiatrists, hypnosis, I went to patches, went to — like I said, everything."
In 1997, Marie quit smoking for four to five months. When she returned to smoking, she told her doctor she did so "due to social influences." In December, 2001, a medical oncologist informed her that she likely had metastatic small cell lung cancer. Within seven months of that diagnosis, she was dead. The parties stipulated that smoking caused the lung cancer that led to her death.
a. Tar. The particulates that result from burning tobacco are collectively known as "tar." "The tar is the taste in a cigarette," so a smoker would "have a better taste experience from the product" if the cigarette were designed to allow more of the tar through the filter. However, the tar is the element in cigarettes with the carcinogenic chemicals that, with repeated exposure, cause cancer. If a cigarette manufacturer designed the cigarette to reduce the amount of tar the consumer inhales when smoking a cigarette, the manufacturer would reduce the risk of the consumer developing cancer, unless the consumer were to compensate by inhaling harder on the cigarette or smoking more cigarettes.
b. Nicotine. Nicotine is a chemical that exists naturally in tobacco plants. When a cigarette is smoked, the nicotine in the tobacco is carried on the tar into the lungs. From there, the nicotine gets absorbed into the bloodstream and arrives at the brain within about seven to ten seconds. In the brain or in the lungs, nicotine binds to certain "nicotinic receptors," which triggers the release of various hormones. The most critical hormone that is released by the binding of nicotine to its receptors is dopamine, a chemical that "has the attribute of making you feel good." By triggering the release of dopamine, nicotine can partially satisfy the craving for food, which is why those who smoke have an easier time keeping their weight down. Nicotine also stimulates the release of norepinephrine, creating a stimulant effect that helps a smoker wake up and feel more alert. Nicotine can also enhance the release of acetylcholine, which can assist with arousal and cognitive function; stimulate the release of serotonin, which can modulate mood and potentially help with depressed feelings; and stimulate the release of endorphins and gamma amino butyric acid, which reduce anxiety and tension.
Nicotine is as or more addictive than any other drug of abuse, including heroin and cocaine. Even Lorillard's expert, Dr. Kathleen Brady, an addiction psychiatrist, agreed with the description of nicotine dependence as a "severe illness." In an article Brady coauthored, nicotine is described as "among the most addictive substances known," and the article asserted that "there's a greater likelihood that a person who starts smoking will become dependent than a person who starts using heroin," cocaine, or alcohol. As a smoker continues to expose herself to nicotine, the smoker's brain will develop new receptors to get the effect of the drug. This effect, known as "drug tolerance," results in the smoker needing more nicotine to get the same effect from smoking. Furthermore, repeated smoking of cigarettes with addictive levels of nicotine results in a physiological change known as neuroplasticity, "which basically means that new brain circuits or connections are made with administration of nicotine," and these changes appear to last for months or years. The result of these physiological changes arising from the use of nicotine is that the addicted smoker begins to feel withdrawal symptoms when she does not have the nicotine level to which she is accustomed in her body. As Dr. Cummings testified:
"Within about twenty minutes, for the typical smoker, the nicotine levels are beginning to plummet. And a lot of addicted smokers will find themselves ... within thirty minutes, forty minutes with a little antsy feeling in the pit of their stomach. They are then looking to have a cigarette.... People begin to go into withdrawal, literally, within hours after they quit smoking and find it hard to stay off.... You take a drag on a cigarette, that goes away."
While the strength of an individual's nicotine addiction will vary with the average number of cigarettes smoked each day, a young person smoking just one cigarette per day and an adult smoking five cigarettes per day will suffer from addiction. The addiction strengthens over time, and the earlier a person starts smoking, the harder it is to quit. Most smokers start early in life. The average age at which individuals begin to smoke is fourteen and one-half years, two-thirds start by the age of eighteen, and few start after the age of twenty-five.
The addictive power of nicotine is reflected in the testimony of Dr. Cummings that there are approximately 48 million smokers in the United States, of whom approximately seventy per cent want to quit, but only approximately 17 million actually try each year to quit. Of those who try to quit, only three per cent succeed in not smoking for six months.
c. Menthol. Menthol is a chemical derived from mint. Adding menthol to cigarettes makes the smoke less likely to cause a harsh sensation and trigger a gag reflex by anesthetizing the sensory organs in the throat. By making cigarette smoke milder and easier to inhale, menthol makes it easier for some young people to start to smoke. The addition of menthol also affects the flavor of the smoke; approximately thirty per cent of smokers in the United States prefer mentholated cigarettes. Apart from making it easier for some people to start smoking, menthol does not materially affect the delivery of tar or nicotine in the cigarette and is not itself either carcinogenic or addictive.
Discussion. 1. Implied warranty of merchantability. Under the wrongful death statute, G. L. c. 229, § 2, Lorillard is liable if its negligence or wilful, wanton, or reckless act caused Marie's death, or if it "is responsible for a breach of warranty arising under Article 2 of [G. L. c. 106]" that caused her death. Under G. L. c. 106, § 2-314(2)(c), of the Uniform Commercial Code, apart from exceptions not applicable here, a warranty that goods, such as cigarettes, are merchantable is implied in a contract for their sale, and goods are merchantable if they are "fit for the ordinary purposes for which such goods are used." "A seller breaches its warranty obligation when a product that is defective and unreasonably dangerous' ... for the [o]rdinary purposes' for which it is `fit' causes injury." Haglund v. Philip Morris Inc., 446 Mass. 741, 746 (2006) (Haglund), quoting Colter v. Barber-Greene Co., 403 Mass. 50, 62 (1988) (Colter). A product may be defective and unreasonably dangerous because of a manufacturing defect, a design defect, or a warning defect, that is, a failure reasonably to warn of the product's foreseeable risks of harm. See Restatement (Third) of Torts: Products Liability § 2, at 14 (1998) (Third Restatement) ("product is defective when, at the time of sale or distribution, it contains a manufacturing defect, is defective in design, or is defective because of inadequate instructions or warnings"). Here, the plaintiff alleged, and the jury found, a design defect and a warning defect, with the warning defect limited to the period before 1970. While these defects are separate and distinct and may each be found to have caused Marie's death, the special verdict form asked the jury whether "any breach of warranty" caused Marie's death, and did not ask the jury to make separate findings of causation as to the design defect and the warning defect. Because we cannot know whether the jury found that one or both defects caused her death, the breach of implied warranty claim may survive only if the jury were properly instructed as to both theories and the evidence as to both theories is sufficient to support the verdict.
On appeal, Lorillard claims various errors regarding these two theories of liability. First, Lorillard claims that the judge erred by instructing the jury that, in determining whether the product's design was reasonably safe, they "may also consider" whether Newport cigarettes met consumers' reasonable expectations as to safety, rather than that they "must" consider consumers' reasonable expectations. Lorillard contends that the plaintiff was required to prove that Newport cigarettes were more dangerous than consumers reasonably expected, and that the plaintiff offered no evidence to meet this required element of proof. Second, it argues that the plaintiff failed to prove a safer alternative design that would be an acceptable substitute to ordinary smokers, and that therefore the jury could not have found Newport cigarettes to be defective based on their levels of tar and nicotine without finding that all cigarettes are defective, thereby imposing categorical product liability on cigarettes. Third, it claims that the evidence is insufficient to support the jury's finding of a failure to warn, because the health risks from cigarettes were obvious to all before 1970 and there is no duty to warn of an obvious risk. We address each of Lorillard's claims in turn.
a. Reasonable consumer expectations of product safety. By arguing that the judge erred in instructing the jury that they "may" consider whether Newport cigarettes met consumers' reasonable expectations as to safety, rather than that they "must" do so, Lorillard is effectively asking us to adopt the reasonable consumer expectations standard for design defect in comment i to § 402A of the Restatement (Second) of Torts, adopted in 1965 (Second Restatement), rather than the risk-utility balancing standard in § 2 of the Third Restatement.
Under § 402A of the Second Restatement, a seller is liable for physical harm caused to the ultimate user if it "sells any product in a defective condition unreasonably dangerous to the user or consumer or to his property." Second Restatement, supra at § 402A, at 347. Comment i to § 402A recognizes that "[m]any products cannot possibly be made safe for all consumption," and defines an "unreasonably dangerous" product as one that is "dangerous to an extent beyond that which would be contemplated by the ordinary consumer who purchases it, with the ordinary knowledge common to the community as to its characteristics." Second Restatement, supra at § 402A comment i, at 352. Comment i directly addresses when tobacco would be unreasonably dangerous: "Good tobacco is not unreasonably dangerous merely because the effects of smoking may be harmful; but tobacco containing something like marijuana may be unreasonably dangerous." Id.
Under § 2 of the Third Restatement, "[a] product ... is defective in design when the foreseeable risks of harm posed by the product could have been reduced or avoided by the adoption of a reasonable alternative design ... and the omission of the alternative design renders the product not reasonably safe." Third Restatement, supra at § 2(b), at 14. Under what the Third Restatement describes as its reasonableness or risk-utility balancing test, a plaintiff must prove that a reasonable alternative design "was, or reasonably could have been, available at time of sale or distribution," that would have reduced the foreseeable risks of harm posed by the product at reasonable cost, and that the failure to adopt the safer alternative was unreasonable. See Third Restatement, supra at § 2 comment d, at 19. See also Third Restatement, supra at § 2 comment f, at 24. In determining whether a reasonable alternative design was practicable, a trier of fact may consider whether the alternative design is in actual use and whether it is common practice in the industry, but if expert testimony establishes that "a reasonable alternative design could practically have been adopted, a trier of fact may conclude that the product was defective notwithstanding that such a design was not adopted by any manufacturer, or even considered for commercial use, at the time of sale." Third Restatement, supra at § 2 comment d, at 20.
"A broad range of factors may be considered in determining whether an alternative design is reasonable and whether its omission renders a product not reasonably safe. The factors include, among others, the magnitude and probability of the foreseeable risks of harm[;] the instructions and warnings accompanying the product[;] the nature and strength of consumer expectations regarding the product, including expectations arising from product portrayal and marketing[;] [t]he relative advantages and disadvantages of the product as designed and as it alternatively could have been designed[;] the likely effects of the alternative design on production costs; the effects of the alternative design on product longevity, maintenance, repair, and esthetics; and the range of consumer choice among products...."
Third Restatement, supra at § 2 comment f, at 23.
While consumer expectations may be considered in the risk-utility balancing, the Third Restatement makes it clear that, in sharp contrast with the Second Restatement, "consumer expectations do not play a determinative role in determining defectiveness." Third Restatement, supra at § 2 comment g, at 27. "The mere fact that a risk presented by a product design is open and obvious, or generally known, and that the product thus satisfies expectations, does not prevent a finding that the design is defective." Id. at 28. Thus, the Third Restatement recognizes the possibility that a product may be made significantly safer through a reasonable alternative design even when consumers, unaware of the alternative design, expect the product to be no safer than it is.
The vast majority of States have adopted the risk-utility balancing test of the Third Restatement rather than the consumer expectations test of the Second Restatement. See Branham v. Ford Motor Co., 390 S.C. 203, 220-222 & nn.11-14 (2010), and cases cited ("By our count 35 of the 46 states that recognize strict products liability utilize some form of risk-utility analysis in their approach to determine whether a product is defectively designed"); 1 D.G. Owen, M.S. Madden, & M.J. Davis, Products Liability § 8:4, at 449-451 (3d ed. 2000) ("At the inception of the new millennium, the risk-utility test is indubitably the dominant test for design defectiveness"); Twerski & Henderson, Manufacturers' Liability for Defective Product Designs: The Triumph of Risk-Utility, 74 Brook. L. Rev. 1061, 1106-1108 (2009) ("The overwhelming majority of cases that rely on consumer expectations as the theory for imposing liability do so only in res ipsa-like situations in which an inference of defect can be drawn from the happening of a product-related accident"); Note, The Increasing Acceptance of the Restatement (Third) Risk Utility Analysis in Design Defect Claims, 4 Nev. L.J. 609, 616, 625 (2004) ("an increasing number of jurisdictions recognize the usefulness of the Restatement's risk-utility analysis," and "[o]f the jurisdictions that continue to explicitly or implicitly reject the risk-utility analysis set forth by the [Third Restatement], the courts provide little justification for their holdings and bind themselves by nothing other than outdated precedent").
Since 1978, well before the Third Restatement was adopted, we have recognized that consumer expectations are simply a factor, albeit an important factor, in determining whether a product is unreasonably dangerous. See Back v. Wickes Corp., 375 Mass. 633, 642 (1978) (Back) ("fitness" of product "and all others of the same design is a question of degree, depending largely, although not exclusively, on reasonable consumer expectations"). See also Haglund, supra at 748. Cf. Colter, supra at 57 ("manufacturer is in the best position to recognize and eliminate the design defects"). Since 1978, we have also recognized that the determination whether a product is unreasonably dangerous depends on many factors, including "the gravity of the danger posed by the challenged design, the likelihood that such danger would occur, the mechanical feasibility of a safer alternative design, the financial cost of an improved design, and the adverse consequences to the product and to the consumer that would result from an alternative design." Haglund, supra, quoting Back, supra. And since 1978 we have recognized that a product may be found unreasonably dangerous even where all the products in the industry were designed with the alleged defect and where the product conformed to all safety standards in the industry. Back, supra at 643. In short, in determining whether a product's design is unreasonably dangerous, we have been applying a risk-utility balancing standard, where consumer expectations are a factor but not necessarily the determinative factor, since well before the Third Restatement articulated this liability standard.
The defendant argues that we explicitly adopted the Second Restatement's consumer expectations test as the determinative standard of whether a product is unreasonably dangerous in Commonwealth v. Johnson Insulation, 425 Mass. 650, 660-661 (1997) (Johnson Insulation). There, quoting comment i to § 402A of the Second Restatement, we declared, "An article is not unreasonably dangerous merely because some risk of harm is associated with its use, but only where it is dangerous to an extent beyond that which would be contemplated by the ordinary consumer who purchases it, with the ordinary knowledge common to the community as to its characteristics.'" However, this assertion is dictum in the *Johnson Insulation* case, because the basis for finding the product unreasonably dangerous in that case was a warning defect, not a design defect. Id. at 661 ("both the Commonwealth and Johnson focused on the failure to warn' basis for finding a product unreasonably dangerous, and we therefore address only that issue"). In addition, immediately after the assertion relied on by the defendant, we noted in the Johnson Insulation case that the fitness of a product is judged by its "social acceptability, considering such factors as consumer expectations, degree of danger, feasibility and cost of alternative designs, and adverse consequences of alternatives," Johnson Insulation, supra, citing Back, supra at 640-642. Thus, we do not interpret Johnson Insulation to hold that, under Massachusetts law, the reasonable expectations of the ordinary consumer constitute the sole, determinative factor in determining liability for a breach of the implied warranty of merchantability based on defective design. Rather, we continue to uphold the risk-utility balancing standard, where consumer expectations are one of many factors that may be considered in determining whether a product's design is defective.
Therefore, the judge did not err in instructing the jury that they "may," rather than that they "must," consider whether Newport cigarettes met consumers' reasonable expectations as to safety. And because reasonable consumer expectations are simply one of many factors that may be considered and not necessarily the determinative factor, the plaintiff was not obligated to prove that Newport cigarettes were more dangerous than consumers reasonably expected. See Third Restatement, supra at § 2 comment f, at 23 ("plaintiff is not necessarily required to introduce proof on all of these factors; their relevance, and the relevance of other factors, will vary from case to case").
b. Reasonable alternative design of a cigarette. "To establish a prima facie case of defect, the plaintiff must prove the availability of a technologically feasible and practical alternative design that would have reduced or prevented the plaintiff's harm." Third Restatement, supra at § 2 comment f, at 24. See Colter, supra at 57, quoting Uloth v. City Tank Corp., 376 Mass. 874, 881 (1978) ("there is a case for the jury if the plaintiff can show an available design modification which would reduce the risk without undue cost or interference with the performance of the machinery").
The plaintiff presented evidence at trial that cigarettes are a highly engineered product, that the defendant manipulated its product to give the smoker a particular dose of tar and nicotine, that an addictive level of nicotine was approximately 0.4 to 0.5 milligrams of nicotine per cigarette, and that Lorillard never sold a cigarette with nicotine levels at or below 0.4 milligrams per cigarette. Dr. Farone testified that there are "some fifty-seven or fifty-eight different things that one takes into account in designing a cigarette to deliver a certain amount of tar and a certain amount of nicotine." The plaintiff proposed as a reasonable alternative a cigarette without menthol where the carcinogens in the tar are at a level that is relatively safe and where the level of nicotine is nonaddictive. Dr. Farone testified that this could be accomplished by using a "filter that has a very, very high efficiency" and perforating the filter with holes "such that when you suck on it or draw on it, very little smoke comes out," or by using "expanded tobacco," which is tobacco that has had the nicotine removed and has become very light "so when you burn it, you have very little tar." To avoid the complete loss of flavor, Dr. Farone testified that a cigarette manufacturer such as Lorillard could put a flavor on the filter, "so when the air draws back in you get that flavor." He noted that, to design a cigarette with a nonaddictive level of nicotine, "you have to get virtually all of it out" to avoid the risk that smokers will become addicted to the remaining nicotine, and maintain or increase their risk of cancer by puffing harder or smoking more cigarettes.
There was abundant evidence that this alternative was technologically feasible. Patents to extract nicotine from tobacco have existed since the 1920s, and Dr. Farone stated that "certainly by the 1940s there was technology available to remove nicotine from tobacco." Dr. Cummings testified that it is commercially feasible to design and manufacture cigarettes that have nonaddictive levels of nicotine. He gave as one example "Quest 3," which he described as a nonaddictive cigarette with "very low levels of nicotine" that has been available for sale in stores. When Dr. Farone was asked whether there are commercially successful products on the market with 0.03 milligrams of nicotine or lower, he testified that cigarettes at "the lowest end of the scale ... have been sold for many years." As examples of cigarettes for sale in the market with extremely low nicotine and tar outputs, he cited "Carlton, as developed by American Tobacco Company ...; the NOW cigarette from R.J. Reynolds; and the Cambridge from Philip Morris," each of which contained less than 0.05 milligrams of nicotine in the 1980s, and concluded:
"[A]ll we're saying is that the safer cigarettes would meet the criteria in that they wouldn't have nicotine at sufficient levels to addict you, and they wouldn't have chemicals in it at sufficient levels to cause cancer at a reasonable percentage. Every cigarette could meet that. You could have a Marlboro that meets it. You could have a Newport Menthol that meets it. You've just got to reduce the level in the product using technology that we've been talking about that Lorillard had available ... to achieve those numbers."
There was also evidence that a safer alternative cigarette was feasible as to cost. According to a 1977 Lorillard memorandum, the manufacturing costs for a hypothesized Lorillard cigarette with "ultra-low tar" and 0.35 milligrams of nicotine per cigarette would be higher than usual, but "these costs would be more than offset by the reduction in the amount of tobacco used."
Lorillard, however, contends that, even if a low tar, low nicotine cigarette were a technologically feasible alternative design that could be produced at comparable cost, it was not a reasonable alternative design because "carcinogenic levels of tar and addictive levels of nicotine ... are inherent in all ordinary cigarettes," and the "inherent risks of smoking ... cannot be removed without fundamentally altering the nature of the product." The jury rejected this argument through their verdict. Even though Lorillard pressed this point in closing argument, and the judge instructed the jury that in determining whether the product's design was reasonably safe they "should consider, among other factors, ... any adverse consequences to the product and to the consumer that would result from an alternative design, and whether the proposed modification would cause undue interference with the performance of the product," the jury nonetheless found that Newport cigarettes were defective and unreasonably dangerous.
Having failed to persuade the jury, Lorillard contends on appeal that the evidence at trial was insufficient as a matter of law to support a finding of a reasonable alternative design. It essentially makes two arguments. First, it contends that the alternative design proffered at trial was not truly a cigarette, and that the jury essentially found that all cigarettes were defective, thereby imposing categorical product liability on all cigarettes. We agree with Lorillard that, in a case where the allegedly defective product is a cigarette, the reasonable alternative design must also be a cigarette, and that a jury may not impose categorical liability on all cigarettes. See Kyte v. Philip Morris Inc., 408 Mass. 162, 172 (1990) (suggesting claim that "all cigarettes are bad" would fail or be preempted). But the evidence was more than sufficient to permit a reasonable jury to conclude that the alternative design proffered by the plaintiff was a cigarette, especially where the plaintiff's experts identified brands of cigarettes that implement the alternative design that have long been sold commercially as cigarettes. We do not accept Lorillard's implicit suggestion that every cigarette, to be a cigarette, must contain levels of tar that cause a high risk of cancer and levels of nicotine that are addictive. The plaintiff in this case provided substantial evidence of cigarettes on the market that do not contain such levels of tar or nicotine.
Second, Lorillard contends that, even if the alternative design proffered by the plaintiff were a cigarette, the reduced tar and nicotine in that alternative cigarette so fundamentally alters the nature of the product that no reasonable jury could find that it was a reasonable alternative to Newport cigarettes. Lorillard cannot prevail here merely by asserting that the alternative design is not an "ordinary cigarette," which Lorillard defines as a cigarette with carcinogenic levels of tar and addictive levels of nicotine. We have consistently held that a product may be defectively designed even if the characteristic that makes the product unreasonably dangerous is shared with every other competitive product on the market. See Haglund, supra at 748 ("plaintiff need only convince the jury that a safer alternative design was feasible, not that any manufacturer in the industry employed it or even contemplated it"); Back, supra at 636 (manufacturer of motor home found liable in design defect case even though "vehicle conformed to all product safety standards prevailing in the industry" when vehicle was manufactured). "Thus, warranty liability may be imposed even where the product... conformed to industry standards ... and passed regulatory muster...." Haglund, supra. Here, Lorillard's claim that all "ordinary cigarettes" have the same design flaws alleged by the plaintiff does not protect Lorillard from liability, and the judge did not err in declining to instruct the jury that the plaintiff had to prove that a defect was present in Lorillard's cigarettes that was not present in other cigarettes on the market.
The essential question is not whether the safer alternative design is an "ordinary cigarette" but whether adoption of the safer alternative design would result in undue interference with the cost or performance of the product, thereby making the alternative unreasonable. See Colter, supra at 57; Uloth v. City Tank Corp., supra at 881. Whether any interference with the cost or performance of the product is "undue" is generally a question for the jury, because many safer alternatives may increase the cost of a product or interfere to some degree with its performance, such as where the addition of a safety shield to a machine tool makes it both more expensive and harder and slower to operate. But the question becomes one of law where, viewing the evidence in the light most favorable to the plaintiff, the interference with the cost or performance of the product is so substantial that no reasonable jury could conclude that it offers a reasonable alternative to consumers of the product. For example, an automobile is not a reasonable alternative to a motorcycle, even if it were proven safer, solely because it has four wheels rather than two. To add two wheels to a motorcycle would create a fundamentally different product and destroy the product's distinct utility in the eyes of any potential consumer. See Third Restatement, supra at § 2 comment f, illustration 9, at 26-27.
Lorillard contends that the safer alternative cigarette proffered by the plaintiff is not a reasonable alternative as a matter of law because, as the plaintiff's experts conceded at trial, "ordinary smokers" — meaning smokers who are addicted to the nicotine in tobacco — will not smoke cigarettes that will not provide them with the nicotine they crave to satiate their addiction, which is why the alternative cigarettes that are commercially sold have a small share of the market. Before we address this argument, we look first to the expert testimony offered at trial regarding what motivates people to smoke. Drs. Benowitz and Cummings testified that those who start smoking do so for social reasons, not for nicotine. Dr. Cummings noted that, at first, "[m]ost people get a little light-headed, they may even get nauseous, and you overcome that usually because your friends are" smoking. He added that when people start to smoke, they are freely making a choice to smoke, and the choice, especially for teenagers, is usually for "psychosocial reasons." However, once one goes beyond the experimentation phase and "you get into the daily use pattern, your choice to smoke becomes diminished by the physiological effects of nicotine on your brain.... It's the daily use pattern ... that distinguishes somebody ... smoking for nicotine from somebody who is not smoking for nicotine." Dr. Benowitz testified that, with continued exposure to nicotine, "smoking changes from social smoking to drug-reinforced smoking or to pharmacologic smoking." Once people become regular, daily smokers, what keeps them smoking is nicotine addiction. The evidence at trial was that Lorillard manipulated the level of nicotine in its cigarettes to ensure that those who smoked would continue to be addicted to nicotine. The evidence at trial also showed that the addiction produced by "ordinary" levels of nicotine in cigarettes is so powerful that, in a given year, approximately seventy per cent of cigarette smokers want to stop smoking, but only approximately one-half of those who wish to quit will attempt to quit and, of those who attempt to quit, only approximately three per cent will succeed.
Therefore, the evidence at trial would adequately support a finding that a cigarette with low tar and nicotine was a reasonable alternative to an individual who retained the unimpaired ability to make a rational, informed choice whether to smoke, such as an individual who was considering whether to start smoking or an individual who smoked infrequently or in small quantities. However, the plaintiff's proposed alternative cigarette was not a reasonable alternative to one who already was addicted to nicotine, whose freedom of choice was physiologically impaired by the effects of the nicotine. In short, the evidence in this case is sufficient to support a finding that low tar, low nicotine cigarettes are a safer, reasonable alternative design to the design used by Lorillard in their Newport cigarettes for the subclass of cigarette consumers who are not yet addicted but is not sufficient to support a finding that such cigarettes are a reasonable alternative for the subclass of consumers who are already addicted.
The question, then, is which subclass of consumers should be considered in evaluating the reasonableness of the alternative design? Lorillard's argument, stripped to its essence, is that the chemical in a product that causes consumers to be powerfully addicted to the product can never be found to constitute an unreasonably dangerous defect because no alternative design that did not contain addictive levels of the chemical will satisfy addicts' craving for the chemical and therefore be purchased by those addicted. If this argument were to prevail, addictive chemicals would be the only substance whose presence in a product could not, as a matter of law, be found to constitute a defect in the product's design, because there could be no reasonable alternative design that did not include them. And the more powerfully addictive the chemical, the more it would be protected from product liability.
We decline to place addictive chemicals outside the reach of product liability and give them special protection akin to immunity based solely on the strength of their addictive qualities. To do so would eliminate any incentive for cigarette manufacturers to make safer perhaps the most dangerous product lawfully sold in the market through reasonable alternative designs. Rather, we conclude that, in determining as a matter of law whether the evidence presented at trial was sufficient for a reasonable jury to conclude that the plaintiff's proposed design was a reasonable alternative to the defendant's product, we must determine whether the design alternative unduly interfered with the performance of the product from the perspective of a rational, informed consumer, whose freedom of choice is not substantially impaired by addiction. Applying that standard to the evidence in this case, we conclude that a reasonable jury could find from the evidence presented that a low tar, low nicotine cigarette constituted a safer reasonable alternative to Lorillard's Newport cigarettes.
Few courts appear to have addressed this question, perhaps because the only legally sold product so addictive as to raise the question is nicotine, and the courts that have done so provide little relevant guidance. The United States Court of Appeals for the Seventh Circuit, in evaluating whether "the average consumer at the time in question" fully appreciated the health risks of smoking, recognized that it needed to "define this imaginary `average consumer.'" Insolia v. Philip Morris Inc., 216 F.3d 596, 599 (7th Cir. 2000). Recognizing "[n]icotine's addictive grip," the court concluded that "the state of knowledge of the average consumer must be measured before the average person is hooked and is no longer capable of making a rational choice." Id.
The Florida Supreme Court affirmed a jury's finding that a cigarette manufacturer had committed a breach of the implied warranty of merchantability where an alleged defect in the cigarettes' design was the addictive level of nicotine, but the court did not set forth its reasons for affirming this finding. Engle v. Liggett Group, Inc., 945 So.2d 1246, 1276-1277 (Fla. 2006), cert. denied sub nom. R.J. Reynolds Tobacco Co. v. Engle, 552 U.S. 941 (2007).
In contrast, in Adamo v. Brown & Williamson Tobacco Corp., 11 N.Y.3d 545, 549 (2008), cert. denied, 558 U.S. 874 (2009), the New York Court of Appeals declared that the plaintiffs alleging the defective design of a particular brand of cigarettes were required to prove as "an essential element" of their case "that regular cigarettes and light' cigarettes have the same utility." The court ruled that "[t]he only utility' of a cigarette is to gratify smokers' desires for a certain experience, and plaintiffs did not prove, or try to prove, that light cigarettes perform this function as well as regular cigarettes." Id. The court did not address the issue of addiction and, therefore, did not discuss whether the gratification of "smokers' desires for a certain experience" was the gratification of a craving arising from nicotine addiction, or whether the utility of a cigarette to a nonaddicted consumer is the same as to one who is addicted.
Because cigarettes are unique among lawfully sold products in being so powerfully addictive, it is doubtful that our ruling requiring a reasonable alternative design to be evaluated through the eyes of a rational, informed consumer, whose freedom of choice is not substantially impaired by addiction, will have any significant consequence on liability actions involving any other product. In Haglund, supra at 751-752, we recognized that cigarettes are unusual in that any reasonable use of the product is foreclosed by the dual risks of serious disease and addiction, and we therefore barred cigarette manufacturers in most circumstances from offering as a defense in a product liability action the plaintiff's unreasonable use of cigarettes, the so-called Correia defense. See Correia v. Firestone Tire & Rubber Co., 388 Mass. 342 (1983). Just as we needed in Haglund to adapt our product liability jurisprudence to the inherent danger of smoking, so too do we need here to adapt our product liability jurisprudence to the inherent addictive potency of certain cigarettes. And just as the defendants in that case argued that we had eviscerated the Correia defense, so too does the defendant here contend that we will be paving the way for product liability claims that nonalcoholic whiskey and beer are reasonable alternatives to whiskey and beer. Such fears are wholly unwarranted. In contrast with cigarette smokers, the vast majority of whiskey and beer drinkers are not addicted to alcohol, so limiting the risk-utility evaluation of a reasonable alternative design to the perspective of rational, informed consumers of these products would have no bearing on the risk of product liability for these beverages.
Finally, even though the evidence was essentially undisputed that the tar and nicotine in Newport brand cigarettes caused Marie's lung cancer, Lorillard argues that no reasonable jury could have found that any design defect in Newport cigarettes caused her death because the evidence at trial was that she tried and rejected a brand of cigarettes with lower tar and nicotine. In making this argument, Lorillard misunderstands the meaning of causation in products liability. Where a plaintiff proves that a product is defective, she may establish causation by proving that the defect caused her injury; the plaintiff need not prove that she would have used a reasonable alternative design had one been available. Colter, supra at 63, quoting Correia v. Firestone Tire & Rubber Co., supra at 355 ("Because warranty liability focuses on whether the product was defective and unreasonably dangerous and not on the conduct of the user or the seller, `the only duty imposed on the user is to act reasonably with respect to a product which he knows to be defective and dangerous'"); Third Restatement, supra at § 1, at 5 (product manufacturer "who sells or distributes a defective product is subject to liability for harm to persons or property caused by the defect" [emphasis added]).
Here, the plaintiff submitted sufficient evidence for a reasonable jury to conclude that the combined effect of the nicotine and tar consumed by smokers of Lorillard's Newport cigarettes was a substantial factor in bringing about Marie's addiction, lung cancer, and wrongful death, and that her injury would have been reduced or avoided had she smoked cigarettes with a reasonable alternative design that would have resulted in a nonaddictive level of nicotine and a reasonably safe level of carcinogenic tar being consumed by the smoker. Lorillard does not escape liability for its defective product simply because an addicted smoker continued to use a product that sated her addiction rather than switch to a safer product that would not do so.
c. Warning defect for the period before 1970. As noted earlier, the jury found that Lorillard violated the implied warranty of merchantability not only because of a design defect, but also because of a warning defect arising from its failure to provide Marie an adequate warning of the health hazards or addictive properties of Newport cigarettes before 1970. Lorillard contends that the evidence was insufficient as a matter of law to support this finding because the risks of smoking were widely reported before Marie started smoking in 1960 and there is no common-law duty to warn of a known or an obvious risk.
"Even if a product is properly designed, it is unreasonably dangerous and, therefore, it is not fit for the purposes for which such goods are used, if foreseeable users are not adequately warned of dangers associated with its use." Hayes v. Ariens Co., 391 Mass. 407, 413 (1984). "However, we have recognized that, `where the danger presented by a given product is obvious, no duty to warn [exists] because a warning will not reduce the likelihood of injury.'" Bavuso v. Caterpillar Indus., Inc., 408 Mass. 694, 699 (1990), quoting Colter, supra at 59. This is consistent with the Third Restatement, which provides, in § 2 comment j, at 31: "In general, a product seller is not subject to liability for failing to warn or instruct regarding risks and risk-avoidance measures that should be obvious to, or generally known by, foreseeable product users."
Marie began to smoke in 1960. In 1965, the United States Congress enacted the Federal Cigarette Labeling and Advertising Act, Pub. L. 89-92, § 4, 89th Cong., 1st Sess., 79 Stat. 282, 283 (Labeling Act), which required all cigarette packages to bear the warning, "Caution: Cigarette Smoking May Be Hazardous to Your Health." Before this requirement took effect in 1966, there were no warnings on retail packages of Newport cigarettes, on free sample packages of Newport cigarettes, or in any advertising materials for Newport cigarettes. Marie testified that she remembered seeing the warning when it first appeared on cigarette packages.
In 1967, the Federal Trade Commission (FTC) issued a report stating that the warning label on cigarette packages had "not succeeded in overcoming the prevalent attitude toward cigarette smoking created and maintained by the cigarette companies through their advertisements, particularly the barrage of commercials on television, which portray smoking as a harmless and enjoyable social activity that is not habit forming and involves no hazards to health." The report concluded that "[c]igarette commercials continue to appeal to youth and continue to blot out any consciousness of the health hazards." In 1970, Congress amended the mandated warning label on cigarette packages to state: "Warning: The Surgeon General Has Determined That Cigarette Smoking Is Dangerous To Your Health," with the warning becoming effective on November 1, 1970. Public Health Cigarette Smoking Act of 1969, Pub. L. 91-222, § 4, 91st Cong., 2d Sess., 84 Stat. 87, 88, 90 (1969 Act). The 1969 Act also declared that, apart from this warning, "[n]o requirement or prohibition based on smoking and health shall be imposed under State law with respect to the advertising or promotion of any cigarettes." Id. at § 5. Because the 1969 Act preempts any State law claim imposing liability based on a showing that a cigarette manufacturer's "post-1969 advertising or promotions should have included additional, or more clearly stated, warnings," Cipollone v. Liggett Group, Inc., 505 U.S. 504, 524 (1992) (Stevens, J., plurality opinion), the plaintiff limited the failure to warn claims to the period ending in 1969.
Viewing the evidence in the light most favorable to the plaintiff, we conclude that a reasonable jury could find that the risks of cigarette smoking were certainly not obvious before 1966, when the warning on cigarette packages ordered by Congress provided only that "cigarette smoking may be hazardous to your health," and were still not obvious before 1970, when the warning was stiffened to declare that "the Surgeon General has determined that cigarette smoking is dangerous to your health" (emphases added). As the United States Court of Appeals for the Sixth Circuit declared in Tompkin v. American Brands, 219 F.3d 566, 572 (6th Cir. 2000):
"The pertinent issue here is not whether the public knew that smoking was hazardous to health at some undifferentiated level, but whether it knew of the specific linkages between smoking and lung cancer. Public awareness of a broad-based and ambiguous risk that smoking might be tenuously connected to lung cancer does not suggest common knowledge' of the known scientific fact that cigarette smoking is a strong precipitant of lung cancer.... It is one thing to be aware generally that a product might have an attenuated and theoretical connection with a deadly disease like lung cancer; it is another altogether to comprehend that it is the cause of an overwhelming majority of lung cancer cases.... The common knowledge' requirement is emasculated if a defendant may show merely that the public was aware that a product presented health risks at some vague, unspecified, and undifferentiated level."
See Burton v. R.J. Reynolds Tobacco Co., 884 F. Supp. 1515, 1526 (D. Kan. 1995) (rejecting assertion "that because there is general common knowledge that cigarettes are dangerous, users of cigarettes are therefore imputed with knowledge of the extent and nature of all dangers relating to cigarettes"). While the general public may have understood before 1970 that cigarettes posed a general risk to health, the plaintiff presented considerable evidence that Lorillard, along with other cigarette manufacturers, engaged in a calculated effort through advertising and public statements to raise doubts whether the causative link between cigarettes and cancer was scientifically proven, and that the FTC in 1967 acknowledged the success of these efforts. In fact, Lorillard has a bit of chutzpah to claim that it was obvious to the general public by 1960 that cigarettes were addictive and caused cancer when, in 1994, during sworn testimony before a congressional subcommittee, Andrew H. Tisch, Lorillard's chairman and chief executive officer, declared that he did not believe that cigarette smoking was addictive or caused cancer.
Lorillard also argues that there is no duty to warn one who is aware of the risk, and that Marie knew cigarettes were dangerous when she started smoking in 1960. "The duty to warn ... does not attach where ... the plaintiff appreciated the danger substantially to the same extent as a warning would have provided." Carey v. Lynn Ladder & Scaffolding Co., 427 Mass. 1003, 1004 (1998). Viewing the evidence in the light most favorable to the plaintiff, a reasonable jury could conclude that Marie was not aware of the health risks of smoking when she started to smoke in 1960 at the age of thirteen and that, in 1964 when she became aware of the publicity surrounding the Surgeon General's report, she did not appreciate the danger of smoking Lorillard's Newport cigarettes to the same extent as a warning would have provided. Her deposition testimony evidenced the extent to which the cigarette manufacturers' efforts to raise doubts as to whether cigarettes caused cancer succeeded: "you really didn't rely on anyone's opinion as to being the true cause of what causes cancer."
Finally, Lorillard argues that there was no evidence that its failure to warn of the foreseeable dangers arising from the use of Newport cigarettes caused Marie's injury because she did not heed the warnings placed on Lorillard's cigarette packages since 1966. We are not persuaded by this argument. In Massachusetts, "[t]he law permits an inference that a warning, once given, would have been followed." Harlow v. Chin, 405 Mass. 697, 702-703 (1989). Once a plaintiff establishes that a warning should have been given, the burden is on "the defendants to come forward with evidence tending to rebut such an inference." Wolfe v. Ford Motor Co., 6 Mass. App. Ct. 346, 352 (1978). There was substantial evidence that, by 1966, Marie was addicted to cigarettes. Evidence that an addicted smoker failed to heed a warning that was given to her after she was already addicted is insufficient to rebut the presumption that, had she received adequate warning before she started smoking, she would have heeded the warning and avoided the addiction.
In conclusion, the jury were appropriately instructed as to both a design defect and a warning defect and, although we do not know whether the jury found causation as to one or both defects, the evidence was sufficient to support the jury's finding on either theory.
As to negligent design, the judge instructed the jury that they "may" but were "not required to consider whether there was a safer alternative design available." This instruction was timely objected to by the defendant at trial and constituted prejudicial error. In claims alleging negligence in the design of a product, as with claims of a design defect in breach of the implied warranty of merchantability, the plaintiff must show "an available design modification which would reduce the risk without undue cost or interference with the performance of the [product]," and the jury must consider whether a safer alternative design was available in deciding whether the defendant was negligent for failing to adopt that design. Colter, supra at 57, quoting Uloth v. City Tank Corp., supra at 881. See Kotler v. American Tobacco Co., 926 F.2d 1217, 1225 (1st Cir. 1990), vacated on other grounds, 505 U.S. 1215 (1992) (in Massachusetts, "[i]n a design defect case premised on negligence, the existence of a safer alternative design is a sine qua non for the imposition of liability"). We have already declared that a reasonable alternative design must be shown before a defendant may be found liable for breach of the implied warranty of merchantability based on a design defect, and "[a] defendant cannot be found to have been negligent without having breached the warranty of merchantability." Haglund, supra at 747 n.9, quoting Colter, supra at 61. Therefore, we conclude that the jury were incorrectly instructed on the law regarding the plaintiff's claim of negligent design.